Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males

Trial Profile

A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Feb 2018 Results from a phase 3 study (000023, NCT01665599) and its 6-month extension study (000077, NCT01703741) assessing the efficacy, safety, local tolerability and pharmacokinetics of testosterone gel 2% in hypogonadal men, published in the Andrologia Journal.
    • 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top